Sat, Aug 23, 2014, 2:17 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cempra, Inc. Message Board

  • alonsocpbariletti alonsocpbariletti Nov 7, 2013 1:51 AM Flag

    ADSU (.015) Just upgraded to a $2 Price Target

    ADSU was just upgraded to a $2 price target by Everest Stock Market Research, add this one to your watch lists immediately we could see huge gains tomorrow morning. The last alert they put a price target on went up over 3000% same day!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is actually the scientific explanation as to why we have not seen serious safety issues.
      The only currently marketed ketolide, telithromycin, suffers from rare, but serious side effects. Recent studies have shown this to be likely due to the presence of the pyridine-imidazole group of the telithromycin side chain acting as an antagonist towards various nicotinic acetylcholine receptors. Since solithromycin, like azithromycin and clarithromycin, lacks this chemical moiety, it is not expected to cause the adverse events seen with Ketek (telithromycin).

    • DRTX is also intriguing and undervalued IMO, however it's scope is more limited. Solithromycin has shown to not only be powerfully effective at treating MRSA infections, but it is available in both PO and IV formulations. You can also probably tack on an additional 1 to 200 million a year of earnings potential for cempras other product in development, taksta.

    • Yes, dickierzphazlitt. It should be further noted that peak earnings for telithromycin were expected to be 1.5 billion prior to the side effects, and also that these same side effects of liver toxicity were not at all present in cempra's phase 2 trial. I too believe that Solithromycin has the same earnings potential that telithromycin once had. With a comparative market cap of JUST 400 million I consider cempra to be a prime buy-and-hold stock.

    • This is actually the scientific explanation as to why we have not seen serious safety issues.
      The only currently marketed ketolide, telithromycin, suffers from rare, but serious side effects. Recent studies have shown this to be likely due to the presence of the pyridine-imidazole group of the telithromycin side chain acting as an antagonist towards various nicotinic acetylcholine receptors. Since solithromycin, like azithromycin and clarithromycin, lacks this chemical moiety, it is not expected to cause the adverse events seen with Ketek (telithromycin).

    • Anyone REAL buying/using this service? Hellooo? I didn't think so.

    • right now that might get overshadowed by something else pretty important happening that date

    • At what point will they be filing a new drug application with the fda for solithromycin do you think? Late 2014?

 
CEMP
9.45+0.08(+0.85%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Keurig Green Mountain, Inc.
NasdaqGSFri, Aug 22, 2014 4:00 PM EDT
Amicus Therapeutics, Inc.
NasdaqGMFri, Aug 22, 2014 4:00 PM EDT